Teprotumumab: a disease modifying treatment for graves’ orbitopathy
Abstract Background On 21st January 2020, the FDA approved Tepezza (teprotumumab-trbw) for the treatment of active Graves’ orbitopathy (GO) in adults. This approval was based on positive results from two multinational randomised double-blind placebo-controlled clinical trials. Discussion This articl...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Thyroid Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13044-020-00086-7 |